Prevent nerve damage during weekly paclitaxel breast cancer treatment
Part of Cancer, Skin clinical trials.
This Phase 2 study tests whether a daily tablet (Onlife) can help prevent nerve side effects (“neurotoxicity”) caused by weekly paclitaxel given for breast cancer. You’d be randomly assigned to the tablet or a placebo, and you would be closely followed with questionnaires and clinic visits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have breast cancer and are starting weekly paclitaxel (80 mg/m²) for 12 treatment doses, either before or after surgery.
- You are 18 years or older, and your general health is good enough for study treatment (Karnofsky score 3 or less).
- If you could become pregnant, you must use effective birth control while taking the study tablets.
- You can swallow the Onlife/placebo tablets and are willing to complete many questionnaires and follow all study visits.
- You have not started paclitaxel already before joining the study, and you are not allergic to the tablet ingredients (including fish-oil related ingredients).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether it's safe to stop the routine allergy-prevention medications (premedication) given before weekly paclitaxel chemotherapy in patients with non-metastatic breast cancer. The goal is to see if stopping these medications improves your quality of life during treatment.
This trial tests whether wearing tight surgical gloves during paclitaxel chemotherapy can prevent nerve damage (neuropathy) in the hands. It's for people with stage II or III breast cancer who are about to start paclitaxel treatment for at least 12 weeks.
This early-phase study tests how epidiferphane works in the body and whether it is safe when combined with standard chemotherapy “taxanes” (paclitaxel or docetaxel) for breast cancer. If you qualify, you may be starting a new taxane treatment plan at the study site, and you would be followed closely for side effects and drug levels.
This study tests a combination of two medicines (albumin-bound paclitaxel and a granulocyte-based therapy) for women with breast cancer that has come back or spread. It may be an option if you have already tried standard treatment and are looking for another approach.
This study looks at how physical activity and body composition affect the side effects of paclitaxel, a chemotherapy drug, in women with stage II or III breast cancer. It aims to help doctors understand who might have more or fewer side effects during treatment.
This study tests whether a new version of paclitaxel (albumin-bound) works the same as the approved version in people with breast cancer. It's for patients whose cancer has spread or returned after other treatments, or those for whom this drug is recommended by treatment guidelines.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.